Related Experiment Video
Updated: May 27, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Anacetrapib: a new weapon against dyslipidemia
Georgios Aperis1, Christos Paliouras, Eirini Tsampikaki
1Nephrology Department, General Hospital of Rhodes, Agioi Apostoloi, Greece. gaperis@yahoo.com
Abstract:
Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. One of the major advantages of this agent is, apart from the significant decrease in LDL-C it produces a substantial increase in HDL-C. Phase I, II, and III clinical trials have shown that anacetrapib is safe alone or in combination with statins. However, longterm clinical trials are required in order to assess whether it reduces mortality in individuals at high-risk of cardiovascular disease.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Pharmacogenomics: Identification of New Drug Targets
Lipid Digestion
Atherosclerosis I: Introduction